THE TOXICITY OF CHEMICALLY DEGLYCOSYLATED RICIN A-CHAIN IN MICE

被引:30
|
作者
SOLERRODRIGUEZ, AM
UHR, JW
RICHARDSON, J
VITETTA, ES
机构
[1] UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235
[2] UNIV TEXAS,DEPT PATHOL,DIV COMPARAT MED,DALLAS,TX 75235
[3] UNIV TEXAS,CTR CANC IMMUNOBIOL,DALLAS,TX 75235
来源
关键词
D O I
10.1016/0192-0561(92)90041-I
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tumor-reactive antibodies coupled to ricin or its A-chain (immunotoxins) have been used in rodents and humans to treat a variety of neoplastic diseases. Side-effects of such treatment include hepatotoxicity, vascular leak syndrome, myalgia and low grade fever. At high doses, severe toxicities include liver damage, pulmonary edema, aphasia, rhabdomyolysis and kidney failure. There have been a limited number of toxicologic studies on uncoupled ricin or its A-chain and none on deglycosylated A-chain. Since the latter has been utilized in "second generation" immunotoxins, the current studies were carried out to evaluate the toxicities induced by deglycosylated ricin A-chain (dgA) in mice. The administration of dgA to normal BALB/c mice causes early (24 h) weight loss and late (10 day) accumulation of ascites. These effects could be partially altered by changing the route of injection of dgA from i.v. to i.p. Thus, i.p. administration caused weight loss but not ascites, whereas i.v. administration caused both. Weight loss was associated with reduced fluid intake by the treated mice, and was not associated with increased levels of serum TNF-alpha. SCID mice injected with the same dose of dgA as normal BALB/c mice developed ascites, but it was of lesser severity, suggesting that a functional immune system, differences in microbial flora, or strain differences may be involved in the development of ascites.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 50 条
  • [31] The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma
    Engert, A
    Sausville, EA
    Vitetta, E
    CLINICAL APPLICATIONS OF IMMUNOTOXINS, 1998, 234 : 13 - 33
  • [32] CIRCULAR-DICHROISM OF ISOLATED RICIN A-CHAIN AND B-CHAIN
    WAWRZYNCZAK, EJ
    DRAKE, AF
    THORPE, PE
    BIOPHYSICAL CHEMISTRY, 1988, 31 (03) : 301 - 305
  • [33] THE EFFECT OF RICIN B-CHAIN ON THE INTRACELLULAR TRAFFICKING OF AN A-CHAIN IMMUNOTOXIN
    TIMAR, J
    MCINTOSH, DP
    HENRY, R
    CUMBER, AJ
    PARNELL, GD
    DAVIES, AJS
    BRITISH JOURNAL OF CANCER, 1991, 64 (04) : 655 - 662
  • [34] EFFECT OF CYCLOPHOSPHAMIDE ON THE IMMUNOGENICITY OF RICIN A-CHAIN IMMUNOTOXIN IN RATS
    HARKONEN, WS
    MISCHAK, R
    STOUDEMIRE, J
    FEDERATION PROCEEDINGS, 1987, 46 (04) : 1507 - 1507
  • [35] EFFECT OF CHEMICAL DEGLYCOSYLATION ON THE INVIVO FATE OF RICIN A-CHAIN
    BLAKEY, DC
    THORPE, PE
    CANCER DRUG DELIVERY, 1986, 3 (03): : 189 - 196
  • [36] USE OF RICIN A-CHAIN TO SELECTIVELY DEPLETE KUPFFER CELLS
    ZENILMAN, ME
    FIANI, M
    STAHL, P
    BRUNT, E
    FLYE, MW
    JOURNAL OF SURGICAL RESEARCH, 1988, 45 (01) : 82 - 89
  • [37] CHIMERIC TOXIN COMPOSED OF VISCUMIN A-CHAIN AND RICIN B-CHAIN
    TONEVITSKII, AG
    TOPTYGIN, AU
    AGAPOV, II
    SHAMSHIEV, AT
    PFUFFLER, U
    ERSHOVA, GV
    PROKOFEV, SA
    RAKHMANOVA, VA
    MOLECULAR BIOLOGY, 1994, 28 (03) : 380 - 383
  • [38] PHARMACOKINETIC STUDIES IN MICE WITH ICI D0490, A NOVEL RECOMBINANT RICIN A-CHAIN IMMUNOTOXIN
    CALVETE, JA
    NEWELL, DR
    CHARLTON, CJ
    WRIGHT, AF
    BRITISH JOURNAL OF CANCER, 1993, 67 (06) : 1310 - 1315
  • [39] The N-terminal ricin propeptide influences the fate of ricin A-chain in tobacco protoplasts
    Jolliffe, Nicholas A.
    Di Cola, Alessandra
    Marsden, Catherine J.
    Lord, J. Michael
    Ceriotti, Aldo
    Frigerio, Lorenzo
    Roberts, Lynne M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (33) : 23377 - 23385
  • [40] Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase
    Bellisola, G
    Fracasso, G
    Ippoliti, R
    Menestrina, G
    Rosén, A
    Soldá, S
    Udali, S
    Tomazzolli, R
    Tridente, G
    Colombatti, M
    BIOCHEMICAL PHARMACOLOGY, 2004, 67 (09) : 1721 - 1731